Professor Sir Andrew Pollard, director of the Oxford Vaccine Group, has said that the UK is "going to have to live with" COVID-19, BBC News reported on Wednesday.
Prof Pollard, speaking to the Commons Science and Technology Committee, was quoted as saying that "variants and their emergence" will "continue to happen".
He added: "But in the end, we're going to have to come back to focusing on the really important public health issue, which is the hospitalisation and the death. If transmission is disconnected by vaccine immunity from the severe disease, to a large extent, then we'll need to monitor new variants, perhaps, if we need to find new vaccines and so on - but we are going to have to live with it being in our communities and transmitting."
Pfizer and BioNTech granted FDA approval for XFG-adapted COVID-19 vaccine
4basebio announces strategic collaboration with Genezen
Charles River and Medigen collaborate on next-generation enterovirus vaccine development
Innorna Nominated for 2026 Prix Galien USA Best Startup Award
Sanofi's MenQuadfi receives EU approval for infants from six weeks
Evaxion to present three-year cancer vaccine data at ESMO Congress 2026
Evaxion presents new preclinical data on cytomegalovirus vaccine EVX-V1
Northwest Biotherapeutics presents on propensity score matching at BNOS 2026
Taiwan biomedical startups hold over 100 business meetings at BIO 2026
SK bioscience to lead Gates Foundation-funded ROTOR project
Anixa Biosciences' breast cancer vaccine technology granted first Korean patent
Transgene expands myvac platform into non-small cell lung cancer with TG4070
Replicate Bioscience awarded Gates Foundation grant to advance srRNA vaccine candidates for TB